Clovis Oncology (CLVS) soars 77% after saying that its CO-1686 lung-cancer drug has offered...

|About: Clovis Oncology (CLVS)|By:, SA News Editor

Clovis Oncology (CLVS) soars 77% after saying that its CO-1686 lung-cancer drug has offered "clear evidence of meaningful activity in a heavily pre-treated patient population" in an ongoing Phase I/II trial. "Metastasis shrinkage has been observed at multiple organ sites," including in the brain and liver. "I guess we were all wrong," tweets Adam Feuerstein. "$CLVS wins #ASCO13." (PR)